Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.
Chithelen J, Lovett DH, Wang K, Torres Yanagisawa AE, Caccin FNM, Iketani S
Nat Commun. 2026 May 19;17(1):6575. doi: 10.1038/s41467-026-73444-y.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 247684 | pLEX307-miRFP680 | Lentivirus compatible Gateway destination vector. For constitutive expression under the EF1alpha promoter with constitutive expression of miRFP680. |
| 247685 | pDONR221-miRFP680 | Gateway cloning compatible entry vector for miRFP680. |
| 247686 | pLEX307-puro-miRFP680 | Constitutively expresses miRFP680 under the EF-1a promoter with puromycin selection marker. |
| 247687 | pLEX307-puro-FlipGFP-SARS-CoV-2-3CLcs | Lentivirus compatible constitutive expression of FlipGFP construct with SARS-CoV-2 3CL cut site (AVLQSGFR) with puromycin resistance marker. |
| 247688 | pLEX307-miRFP680-FlipGFP-SARS-CoV-2-3CLcs | Lentivirus compatible constitutive expression of FlipGFP construct with SARS-CoV-2 3CL cut site (AVLQSGFR) with miRFP680 marker. |
| 247689 | pDONR221-SARS-CoV-2-nsp5 | Gateway cloning compatible entry vector for SARS-CoV-2 nsp5. |
| 247690 | pDONR221-SARS-CoV-2-nsp5-C145A | Gateway cloning compatible entry vector for SARS-CoV-2 nsp5 with C145A mutation. |
| 247691 | pLEX307-puro-SARS-CoV-2-nsp5 | Constitutive expression of SARS-CoV-2 nsp5 under EF1-alpha promoter with puromycin resistance. |
| 247692 | pLEX307-puro-SARS-CoV-2-nsp5-C145A | Constitutive expression of SARS-CoV-2 nsp5 with C145A mutation under EF1-alpha promoter with puromycin resistance. |
| 247693 | pLEX307-puro-SARS-CoV-2-nsp5-T21I | Constitutive expression of SARS-CoV-2 nsp5 with a T21I mutation under EF1-alpha promoter with puromycin resistance. |
| 247694 | pLEX307-puro-SARS-CoV-2-nsp5-L50F | Constitutive expression of SARS-CoV-2 nsp5 with a L50F mutation under EF1-alpha promoter with puromycin resistance. |
| 247695 | pLEX307-puro-SARS-CoV-2-nsp5-E166V | Constitutive expression of SARS-CoV-2 nsp5 with a E166V mutation under EF1-alpha promoter with puromycin resistance. |
| 247696 | pLEX307-puro-SARS-CoV-2-nsp5-E166A | Constitutive expression of SARS-CoV-2 nsp5 with a E166A mutation under EF1-alpha promoter with puromycin resistance. |
| 247697 | pLEX307-puro-SARS-CoV-2-nsp5-S144A | Constitutive expression of SARS-CoV-2 nsp5 with a S144A mutation under EF1-alpha promoter with puromycin resistance. |
| 247698 | pLEX307-puro-SARS-CoV-2-nsp5-T304I | Constitutive expression of SARS-CoV-2 nsp5 with a T304I mutation under EF1-alpha promoter with puromycin resistance. |
| 247699 | pDONR221-SARS-CoV-2-nsp4-nsp5-nsp6 | Gateway compatible entry vector of SARS-CoV-2 nsp4 fused to nsp5 fused to the N-terminus of nsp6. |
| 247700 | pDONR221-SARS-CoV-2-nsp4-nsp5-C145A-nsp6 | Gateway compatible entry vector of SARS-CoV-2 nsp4 fused to nsp5 with a C145A mutation fused to the N-terminus of nsp6. |
| 247701 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 fused to nsp4 and an N-terminal fragment of nsp6 under EF1-alpha promoter with puromycin resistance. |
| 247702 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-C145A-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with C145A mutation fused to nsp4 and an N-terminal fragment of nsp6 under EF1-alpha promoter with puromycin resistance. |
| 247703 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-T21I-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with T21I mutation fused to nsp4 and an N-terminal fragment of nsp6 under EF1-alpha promoter with puromycin resistance. |
| 247704 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-L50F-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with L50F mutation fused to nsp4 and an N-terminal fragment of nsp6 under EF1-alpha promoter with puromycin resistance. |
| 247705 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-E166V-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with E166V mutation fused to nsp4 and an N-terminal fragment of nsp6 under EF1-alpha promoter with puromycin resistance. |
| 247706 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-E166A-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with E166A mutation fused to nsp4 and an N-terminal fragment of nsp6 under EF1-alpha promoter with puromycin resistance. |
| 247707 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-S144A-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with S144A mutation fused to nsp4 and an N-terminal fragment of nsp6 under EF1-alpha promoter with puromycin resistance. |
| 247708 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-T304I-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with T304I mutation fused to nsp4 and an N-terminal fragment of nsp6 under EF1-alpha promoter with puromycin resistance. |
| 254471 | pLEX307-puro-NanoLuc | Constitutively expresses NanoLuc under the EF-1a promoter with puromycin selection marker. |